SCHEMBL16611007

SCHEMBL16611007

COc1nccc2c1c(=O)[nH]n2C1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
KDM4E B2RXH2 1/20 0.39
GRM1 Q13255 1/20 0.38
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.38
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
OPRM1 P35372 2/20 0.36
OPRD1 P41143 2/20 0.36
OPRK1 P41145 2/20 0.36
OGFRL1 Q5TC84 1/20 0.36
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.34
LRRK2 Q5S007 5/20 0.34
PIK3CA P42336 2/20 0.34
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
OPRL1 P41146 1/20 0.33
AURKA O14965 1/20 0.33
JAK2 O60674 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16610992 0.99 ALDH1A1 (0.42) ALDH1A1KDM4EGRM1POLBHPGD
SCHEMBL16610842 0.88 LRRK2 (0.45) DDB1CRBNLRRK2PDE9A
SCHEMBL16611832 0.86 LRRK2 (0.41) ALDH1A1DDB1CRBNOPRM1LRRK2
SCHEMBL16611526 0.83 LRRK2 (0.47) DDB1CRBNOPRM1LRRK2PIK3CA
SCHEMBL16610860 0.71 LRRK2 (0.33) DDB1CRBNLRRK2
SCHEMBL25066214 0.70 GRM1 (0.39) ALDH1A1KDM4EGRM1HPGDOPRM1
SCHEMBL16610740 0.69 MAPT (0.45) HPGDTSHR
SCHEMBL16611288 0.67 MAPK13 (0.33) HPGDLRRK2AURKATYK2
SCHEMBL16610989 0.66 DAO (0.42) ALDH1A1KDM4EPIK3CA
SCHEMBL16611389 0.65 AXL (0.33) ALDH1A1KDM4EGRM1PIK3CAAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251352-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 ALDH1A1 3511/4885KDM4E 456/4885GRM1 3757/4885
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 ALDH1A1 3511/4885KDM4E 456/4885GRM1 3757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.